ArticleFrontiers in immunology2022

Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.

Shujie Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.